Allergic Rhinitis Due to House Dust Mite
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Stallergenes GreerFrance - Antony
2 programs1
1
100 IR house dust mites allergen extract tabletPhase 21 trial
500 IR house dust mites allergen extract tabletPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Stallergenes Greer100 IR house dust mites allergen extract tablet
Stallergenes Greer500 IR house dust mites allergen extract tablet
Clinical Trials (2)
Total enrollment: 392 patients across 2 trials
Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model
Start: Dec 2010Est. completion: Sep 2012355 patients
Phase 2Completed
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents
Start: Jul 2013Est. completion: Sep 201337 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space